扈世民｜中信证券 物流和出行服务首席分析师 S1010519040004 物流｜关税影响探讨（二）：优选内需政策受益的航空、物流和集运龙头 应对外部冲击，政策层近期高度重视"做大做强国内大循环"，采取以旧换新补贴扩 容、特定群体补贴、类"消费券"政策等政策组合提振内需，关注受益内需政策加码的 航空、物流和区域集运龙头。1）航空：面对显著上升的采购成本，我们预计国内各 航司将暂停波音飞机的引进计划，假设从4月9日起国内停止引进波音飞机但保持退出 计 划 ， 则 我 们 测 算 2025/2026 年 三 大 航 的 机 队 增 速 或 降 低 1.5pcts/2.1pcts 至 2.9%/2.9%。若假设延迟波音的退出计划叠加航材采购成本上升，我们预计2025年国 内三大航飞机引进增速或降至1%~2%。关税反制进一步限制航空业供给，票价拐点渐 近，国际油价下跌释放利润空间，关注五一前航空布局机会。2）物流：以旧换新国 补扩容及潜在的消费刺激政策有望传导至需求端，选取品类相关度高的顺周期龙头。 3）区域集运：复盘历史，积极的财政政策有望推动大宗商品需求的修复，2024年内 贸行业CR3接近80%，预计需求变化将传 ...

Group 1: Precision Instruments - The article emphasizes that precision instruments are the cornerstone of modern industry and technology development, with increasing risks from U.S. restrictions [1] - It suggests three main investment lines in China's precision instrument sector: seeking "China's Zeiss" in optical instruments, "China's HP" in electronic measurement instruments, and "China's Thermo Fisher" in analytical instruments [1] Group 2: Chromium Chemicals - The price of metal chromium has significantly increased, with a total price hike of 10,000 yuan per ton since the beginning of 2025, indicating strong demand and supply dynamics [2] - The article recommends investing in leading companies with integrated chromium product layouts due to the favorable market conditions [2] Group 3: Insurance Companies - Insurance companies face challenges in asset-liability matching, with a near 50% allocation to fixed-income assets, leading to risks of interest margin losses [3][4] - The article highlights three strategies for insurance capital to enhance investment returns: participating in private placements, strategic investments, and shareholding strategies [3][4] Group 4: Wind Power - The domestic and international offshore wind power sectors are expected to see sustained growth, with domestic installations projected to exceed 12 GW in 2025, doubling year-on-year [6] - The article suggests focusing on various segments of the offshore wind power supply chain, including turbines, subsea cables, and foundations [6] Group 5: ETF Market - The global ETF market is projected to reach $15.09 trillion by 2024, while China's ETF market remains relatively small and underdeveloped [7] - The article advocates for domestic institutions to innovate product types and enhance liquidity mechanisms to build a sustainable market ecosystem [7]

秦培景｜中信证券 首席策略师 S1010512050004 主题策略｜精密仪器：科技自主柱石，品牌成长良机 精密仪器是现代工业和科技发展的基石。近年来大国竞争日趋激烈，美国对精密仪器 封锁围堵风险提升。研究国内新兴产业发展现状，复盘国际精密仪器巨头崛起经验， 能从多个关键维度帮助我们把握中国精密仪器投资机遇。结合国内精密仪器企业市场 生态，我们建议通过三条主线投资中国精密仪器赛道突围：1）寻找下游应用领域丰 富的光学仪器赛道中的"中国蔡司"；2）寻找受益国内高端制造产业链崛起的电子测 量仪器赛道中的"中国惠普"；3）寻找国产替代弹性十足的分析仪器赛道中的"中国赛 默飞"。 风险因素：中美科技贸易等领域摩擦超预期加剧；宏观经济周期波动风险；科技领域 海外技术迭代速度超预期；技术突破难度较大；市场认知与品牌建设不及预期风险； 资金和人才竞争风险。 王喆｜中信证券 能源与材料产业首席分析师 S1010513110001 铬化工｜金属铬价格跳涨，强烈推荐板块投资机遇 2025年4月18日，振华股份宣布其金属铬产品单吨售价大幅调涨5000元，此前公司已 于2月10日、3月13日连续调涨金属铬单吨售价3000/2000元 ...

Investment Rating - The report maintains a "Recommended" rating for the agriculture, forestry, animal husbandry, and fishery industry [1] Core Views - The report highlights the weak fluctuation of pig prices, with expectations of a downward trend in the short term and a long-term weak operation in 2025 due to increased supply and weak demand [4][14] - The poultry sector may see price improvements due to the impact of tariffs and a shortage of quality breeding stock caused by avian influenza [5][28] - The animal health sector is expected to benefit from improved downstream demand and external expansion opportunities, with rising prices for key products like Tylosin [6][41] - The planting sector is experiencing price fluctuations for major grains, with a focus on the commercialization of genetically modified seeds [8][46] - The feed sector is seeing a decline in prices, with recommendations for companies like Haida Group [8][49] - The pet market continues to grow rapidly, with strong performance from domestic brands and recommendations for companies in the pet food and medical sectors [8][54][57] Summary by Sections Pig Industry - Pig prices are expected to adjust slightly, with a forecast of weak performance in 2025 due to increased supply [4][14] - As of April 10, 2025, the average price of live pigs is 14.6 CNY/kg, with no change from the previous week [14] Poultry Industry - The poultry sector may see price increases due to tariff impacts and a lack of quality breeding stock [5][28] - The average price of broiler chickens is 3.75 CNY/lb, reflecting a weekly increase [28] Animal Health - The animal health sector is experiencing improved profitability, with Tylosin prices rising significantly [6][41] - The report suggests focusing on companies with expected external expansion, such as Reap Bio [6] Planting Sector - Major grain prices are fluctuating, with corn priced at 2199 CNY/ton and wheat at 2422 CNY/ton [8][46] - The report recommends companies involved in genetically modified seed development [8] Feed Sector - Feed prices are declining, with pig feed at 3.35 CNY/kg [8][49] - The report suggests focusing on companies like Haida Group due to expected industry consolidation [8] Pet Industry - The pet market is projected to reach 300.2 billion CNY in 2024, with a growth rate of 7.5% [8][54] - Recommendations include companies like Guobao Pet and Zhongchong Co., which are experiencing significant growth [8][57]

Core Viewpoint - The announcement highlights that the company's subsidiary, Luoyang Huizhong Veterinary Medicine Co., Ltd., has received a new veterinary drug registration certificate for "Penicillin V Potassium Soluble Powder," which is aimed at treating necrotic enteritis in chickens caused by Clostridium perfringens [1][2]. Group 1: New Veterinary Drug Information - The new veterinary drug is named "Penicillin V Potassium Soluble Powder" and is classified as a Category V drug [1]. - The main ingredient is Penicillin V Potassium, which is indicated for treating necrotic enteritis in chickens caused by Clostridium perfringens [2]. - The recommended dosage is 13.5 to 20 mg per kg of body weight for chickens, to be administered once daily for five consecutive days [1]. Group 2: Market Background and Development - The drug was developed in collaboration with Jinan Lingpai Biological Pharmaceutical Technology Co., Ltd. and has been clinically used abroad for many years, demonstrating safety and high efficacy [2]. - The prevalence of coccidiosis in chickens leads to significant economic losses in the poultry industry, and existing treatments can lead to drug resistance and are often expensive [2]. - Currently, there is no available data on the sales and market share of similar products in circulation [3]. Group 3: Regulatory and Market Impact - Before the product can be marketed, it must obtain a veterinary product approval number from the Ministry of Agriculture and Rural Affairs [4]. - The successful acquisition of the new drug certificate reflects the company's commitment to technological innovation and is expected to enhance its market competitiveness [5].

Core Insights - The global animal vaccine market is projected to exceed $14 billion in 2024, following a market size of over $13.5 billion in 2023, with a compound annual growth rate (CAGR) of 10.10% over the past five years [1][8]. Market Overview - Animal vaccines, also known as veterinary vaccines, are products made from pathogenic microorganisms that stimulate the immune system of animals to produce specific antibodies, thereby preventing infectious diseases [1]. - North America, including the United States and Canada, is the largest regional market for animal vaccines, accounting for approximately 45% of the global market share in 2023 [3]. Industry Competition - Leading companies in the global animal vaccine industry offer a diverse range of products, including vaccines for pets, pigs, poultry, ruminants, and aquaculture [5]. - Major players such as Merck Animal Health, Zoetis, and Boehringer Ingelheim have established multiple production bases worldwide, indicating significant production capacity [5]. Company Profiles - **Merck Animal Health**: Offers pet vaccines, pig vaccines, poultry vaccines, and aquaculture vaccines, with 29 production bases across 12 countries, including a major facility in Suzhou, China [6]. - **Zoetis**: Operates production bases in the United States and China, having established its first R&D and production base in China in 2019 [6]. - **Boehringer Ingelheim**: Maintains over 20 production bases globally, with two facilities located in Nanchang and Taizhou, China [6]. - **Hualan Biological Engineering**: Initially focused on blood products, it has become a major producer of influenza vaccines in China, accounting for over 40% of the national market [6]. - **Fubao Animal Health**: Produces vaccines for pigs, poultry, and aquaculture, with production bases in the United States and Suzhou, China [6].

Investment Rating - The industry investment rating is "Leading the Market - A" and the rating is maintained [6] Core Views - The report highlights the impact of avian influenza on breeding restrictions, particularly focusing on white feather chickens [2] - The report indicates a short-term supply-demand game in pig farming, emphasizing the need to monitor weight feedback [22] - The report suggests investment opportunities in the aquaculture sector, noting stable prices in the aquatic products market [58] Summary by Sections 1. Weekly Market Review - The agricultural sector increased by 0.56% this week, ranking second among the Shenwan first-level industries [13] - The animal husbandry and veterinary sectors showed an upward trend, with notable stock performances [16] 2. Livestock Farming - **Pig Farming**: The average price of live pigs is 14.66 CNY/kg, with a week-on-week increase of 0.07% and a two-week increase of 0.31%. The average price of piglets is 647 CNY/head, with a week-on-week increase of 2.70% [22] - **Poultry Farming**: The average price of white feather meat chickens is 7.48 CNY/kg, with a week-on-week increase of 2.05%. The price of meat chicks is 2.98 CNY/chick, with a week-on-week increase of 2.41% [33] - **Aquaculture**: Prices for various aquatic products remain stable, with carp priced at 18.00 CNY/kg and shrimp at 300.00 CNY/kg [58] 3. Investment Recommendations - For pig farming, recommended companies include Wen's Foodstuffs, Muyuan Foods, and Shennong Group. For white feather chicken, focus on companies like Shengnong Development and Yisheng Biotechnology [4] - The report anticipates a tighter supply-demand balance in the first half of 2025, suggesting significant performance improvement potential in the post-cycle sector [4] 4. Industry Events - The report notes that over 35 million acres of grain have been sown nationwide, with a focus on improving yields through modern agricultural practices [69] - Central government support for pig farming is highlighted, particularly in terms of subsidies for breeding sows and fattening pigs [69]

独立董事年度述职报告 上海宝信软件股份有限公司 白云霞独立董事 2024 年度述职报告 作为上海宝信软件股份有限公司（以下简称"公司"）第十届董事会独立 董事，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 等法律法规和《公司章程》《董事会议事规则》《独立董事工作制度》的规 定，独立、诚信、勤勉地履行职责，对公司重大事项发表客观、审慎、公 正的意见，维护公司整体利益和全体股东利益，尤其关注中小股东的合法 权益不受损害。现就 2024 年度履职情况报告如下： 一、独立董事的基本情况 （一）独立董事简历 白云霞，女，1973 年 10 月出生，厦门大学生物学本科、会计学硕士、 博士、北京大学光华管理学院博士后，教授，无党派人士。 曾任西安交大开元集团助理工程师、同济大学经管学院讲师、长江商 学院研究学者；现任同济大学经管学院会计系主任、教授、博士生导师、 长江商学院投资中心研究学者，上海宝信软件股份有限公司独立董事，中 电科数字技术股份有限公司独立董事，上海健麾信息技术股份有限公司独 立董事，上海福贝宠物用品股份有限公司独立董事。 （二）独立董事独立性 报告期内，本人符合《上市公司独立董事管理办法》 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-007 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 新兽药名称：鸡新城疫、传染性支气管炎、禽流感（H9 亚型）、传染性法 氏囊病、禽腺病毒病（Ⅰ群，4 型）五联灭活疫苗（N7a 株+M41 株+HF 株+rVP2 蛋白+Fiber-2 蛋白） 注册分类：一类 主要成分：疫苗中含有灭活的鸡新城疫病毒 N7a 株、鸡传染性支气管炎病 毒 M41 株、禽流感（H9 亚型）病毒 HF 株，纯化过滤的鸡传染性法氏囊病病毒 VP2 蛋白液和Ⅰ群禽腺病毒（4 型）Fiber-2 蛋白液。水相中混合抗原终浓度为鸡 新城疫病毒 N7a 株灭活前病毒含量为 108.5EID50/0.1ml，传染性支气管炎病毒 M41 株灭活前病毒含量为 106.0EID50/0.1ml，禽流感（H9 亚型）病毒 HF 株灭活前病 毒含量为108.0EID50/0.1ml。鸡传染性法氏囊病病毒VP2蛋白液琼扩效价为1∶16， Ⅰ群禽腺病毒（4 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-008 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）及全资子公司洛阳惠中生物 技术有限公司（以下简称"惠中生物"）联合申报的"鸡新城疫、禽流感（H9 亚型）、传染性法氏囊病、禽腺病毒病（Ⅰ群，4 型）四联灭活疫苗（N7a 株+HF 株+rVP2 蛋白+Fiber-2 蛋白）"为新兽药，并于 2025 年 3 月 24 日公示了核发《新 兽药注册证书》（中华人民共和国农业农村部公告第 892 号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：鸡新城疫、禽流感（H9 亚型）、传染性法氏囊病、禽腺病毒 病（Ⅰ群，4 型）四联灭活疫苗（N7a 株+HF 株+rVP2 蛋白+Fiber-2 蛋白） 作用与用途：用于预防鸡新城疫、H9 亚型禽流感、传染性法氏囊病和Ⅰ群 禽腺病毒（4 型）病。7～14 ...